Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.68 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16885934 | 0.95 | KCNH2 (0.63) | KCNH2GRIN2B | |
| SCHEMBL16885936 | 0.95 | KCNH2 (0.76) | KCNH2GRIN2B | |
| SCHEMBL16874560 | 0.94 | KCNH2 (0.74) | KCNH2GRIN2B | |
| SCHEMBL16874756 | 0.94 | KCNH2 (0.61) | KCNH2GRIN2B | |
| SCHEMBL16885945 | 0.92 | KCNH2 (0.59) | KCNH2GRIN2B | |
| SCHEMBL16885956 | 0.92 | KCNH2 (0.70) | KCNH2 | |
| SCHEMBL16885940 | 0.91 | KCNH2 (0.60) | KCNH2 | |
| SCHEMBL16885954 | 0.91 | KCNH2 (0.69) | KCNH2GRIN2B | |
| SCHEMBL16874586 | 0.90 | KCNH2 (0.57) | KCNH2GRIN2B | |
| SCHEMBL16874588 | 0.90 | KCNH2 (0.57) | KCNH2GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| US-20190314358-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190314358-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190117638-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190117638-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-25 | — | — | US | disclosed |
| US-20180250283-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-06 | — | — | US | disclosed |
| EP-3092224-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20160081995-A1 | Selective NR2B Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160081995-A1 | Selective NR2B Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2016-03-24 | — | — | US | disclosed |
| US-9221796-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221796-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221796-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| WO-2015105772-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015105772-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20150191452-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| US-20150191452-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| US-20150191452-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | KCNH2 1017/4885GRIN2B 1/4885 |
| US-20190117638-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | KCNH2 1017/4885GRIN2B 1/4885 |
| US-20190314358-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | KCNH2 1017/4885GRIN2B 1/4885 |
| US-20150191452-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | KCNH2 1017/4885GRIN2B 1/4885 |
| US-20160081995-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | KCNH2 1017/4885GRIN2B 1/4885 |
| US-20180250283-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | KCNH2 1017/4885GRIN2B 1/4885 |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | KCNH2 1017/4885GRIN2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.